Pharmacotherapy in Type 1 Diabetes

Canadian Journal of Diabetes

Volumn 37, Issue SUPPL.1, 2013, Pages

  McGibbon, Angela ^a   Richardson, Cindy ^a   Hernandez, Cheri ^a   Dornan, John ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT;

ARTICLE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN SENSITIVITY; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MAXIMUM PLASMA CONCENTRATION; MOTIVATION; NOCTURNAL HYPOGLYCEMIA; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SATISFACTION; PHARMACODYNAMICS; POSTPRANDIAL STATE; PRACTICE GUIDELINE; QUALITY OF LIFE; SELF CARE; TREATMENT INDICATION; CANADA; DIABETES MELLITUS, TYPE 1;

CANADA; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84876023202     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.01.020     Document Type: Article

References (91)

1. Health Canada website. Accessed February 28, 2013. http://www.hc-sc.gc.ca.
2. Hoogma R.P., Hammond P.J., Gomis R., et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabetic Medicine 2005, 23:141-147.
3. Misso M.L., Egberts K.J., Page M., et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010, 1:CD005103.
4. Pickup J., Mattock M., Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002, 324:705.
5. Tsui E., Barnie A., Ross S., et al. Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 2001, 24:1722-1727.
6. DeVries J.H., Snoek F.J., Kostense P.J., et al. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 2002, 25:2074-2080. Dutch Insulin Pump Study Group.
7. Hirsch I.B., Bode B.W., Garg S., et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005, 28:533-538. Insulin Aspart CSII/MDI Comparison Study Group.
8. Retnakaran R., Hochman J., DeVries J.H., et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004, 27:2590-2596.
9. Monami M., Lamanna C., Marchionni N., Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetologica 2010, 47(suppl 1):S77-S81.
10. Zinman B., Tildesley H., Chiasson J.L., et al. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997, 46:440-443.
11. Bode B., Weinstein R., Bell D., et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002, 25:439-444.
12. Radermecker R.P., Scheen A.J. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 2004, 20:178-188.
13. Siebenhofer A., Plank J., Berghold A., et al. Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy. Diabetologia 2004, 47:1895-1905.
14. O'Connell M.A., Donath S., O'Neal D.N., et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia 2009, 52:1250-1257.
15. Bergenstal R.M., Tamborlane W.V., Ahmann A., et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010, 4:311-320.
16. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
17. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group.
18. DeWitt D.E., Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003, 289:2254-2264.
19. Siebenhofer A., Plank J., Berghold A., et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006, 2:CD003287.
20. Heller S.R., Colagiuri S., Vaaler S., et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type1 diabetes. Diabet Med 2004, 21:769-775.
21. Plank J., Siebenhofer A., Berghold A., et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005, 165:1337-1344.
22. Garg S.K., Rosenstock J., Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 2005, 11:11-17.
23. Gough S. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007, 77:1-15.
24. Schernthaner G., Wein W., Shnawa N., et al. Preprandial vs. post-prandial insulin lispro: a comparative crossover trial in patients with type 1 diabetes. Diabet Med 2004, 21:279-284.
25. Jovanovic L., Giammattei J., Acquistapace M., et al. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size. Clin Ther 2004, 26:1492-1497.
26. Bott U., Ebrahim S., Hirschberger S., et al. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet Med 2003, 20:626-634.
27. Dreyer M., Prager R., Robinson A., et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005, 37:702-707.
28. Warren E., Weatherley-Jones E., Chilcott J., et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004, 8:1-57.
29. Wang F., Carabino J.M., Vergara C.M. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 2003, 25:1541-1577.
30. Dunn C.J., Plosker G.L., Keating G.M., et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 2003, 63:1743-1778.
31. Chapman T.M., Perry C.M. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2004, 64:2577-2595.
32. Rossetti P., Pampanelli S., Fanelli C., et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003, 26:1490-1496.
33. Plank J., Bodenlenz M., Sinner F., et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005, 28:1107-1112.
34. De Leeuw I., Vague P., Selam J.L., et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005, 7:73-82.
35. Garg S., Moser E., Dain M.-P., Rodionova A. Clinical experience with insulin glargine in type 1 diabetes. Diabetes Technol Ther 2010, 12:835-846.
36. Monami M., Marchionni N., Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009, 11:372-378.
37. Szypowska A., Golicki D., Groele L., Pankowska E. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes. Pol Arch Med Wewn 2011, 121:237-245.
38. Chatterjee S., Jarvis-Kay J., Rengarajan T., et al. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes: the Glargine and Aspart Study (GLASS): a randomized cross-over study. Diabetes Res Clin Pract 2007, 77:215-222.
39. Ashwell S.G., Bradley C., Stephens J.W., et al. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care 2008, 31:1112-1117.
40. Porcellati F., Rossetti P., Busciantella N.R., et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007, 30:2447-2452.
41. Ashwell S.G., Gebbie J., Home P.D. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med 2006, 23:879-886.
42. Home P., Bartley P., Russell-Jones D., et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004, 27:1081-1087. Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group.
43. Hermansen K., Fontaine P., Kukolja K.K., et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004, 47:622-629.
44. Kudva Y.C., Basu A., Jenkins G.D., et al. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care 2005, 28:10-14.
45. Ashwell S.G., Amiel S.A., Bilous R.W., et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med 2006, 23:285-292.
46. Bartley P.C., Bogoev M., Larsen J., Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-treat basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008, 25:442-449.
47. Birkeland K.I., Home P.D., Wendisch U., et al. Insulin degludec in type 1 diabetes. A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011, 34:661-665.
48. Vella S., Buetow L., Royle P., et al. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 2010, 53:809-820.
49. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995, 18:1415-1427. The Diabetes Control and Complications Trial Research Group.
50. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997, 46:271-286. The Diabetes Control and Complications Trial Research Group.
51. Egger M., Davey Smith G., Stettler C., et al. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med 1997, 14:919-928.
52. Fanelli C.G., Epifano L., Rambotti A.M., et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993, 42:1683-1689.
53. Bott S., Bott U., Berger M., et al. Intensified insulin therapy and the risk of severe hypoglycaemia. Diabetologia 1997, 40:926-932.
54. Ahern J., Tamborlane W.V. Steps to reduce the risks of severe hypoglycemia. Diabetes Spectrum 1997, 10:39-41.
55. Bolli G.B. How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes. Diabetes Care 1999, 22(suppl 2):B43-B52.
56. Pickup J.C., Sutton A.J. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008, 25:765-774.
57. Battelino T., Phillip M., Bratina N., et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011, 34:795-800.
58. Pickup J.C., Freeman S.C., Sutton A.J. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011, 343:d3805.
59. Torlone E., Fanelli C., Rambotti A.M., et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 1994, 37:713-720.
60. McCrimmon R.J., Frier B.M. Symptomatic and physiological responses to hypoglycaemia induced by human soluble insulin and the analogue lispro human insulin. Diabet Med 1997, 14:929-936.
61. Garg S.K., Gottlieb P.A., Hisatomi M.E., et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 2004, 66:49-56.
62. Garg S.K., Paul J.M., Karsten J.I., et al. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther 2004, 6:589-595.
63. Goldman-Levine J.D., Lee K.W. Insulin detemir: a new basal insulin analog. Ann Pharmacother 2005, 39:502-507.
64. Mullins P., Sharplin P., Yki-Jarvinen H., et al. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007, 29:1607-1619.
65. Clarke W.L., Cox D.J., Gonder-Frederick L.A., et al. The relationship between nonroutine use of insulin, food, and exercise and the occurrence of hypoglycemia in adults with IDDM and varying degrees of hypoglycemic awareness and metabolic control. Diabetes Educ 1997, 23:55-58.
66. Fritsche A., Stumvoll M., Renn W., et al. Diabetes teaching program improves glycemic control and preserves perception of hypoglycemia. Diabetes Res Clin Pract 1998, 40:129-135.
67. Cryer P.E., Fisher J.N., Shamoon H. Hypoglycemia. Diabetes Care 1994, 17:734-755.
68. Kaufman F.R., Halvorson M., Kaufman N.D. A randomized, blinded trial of uncooked cornstarch to diminish nocturnal hypoglycemia at diabetes camp. Diabetes Res Clin Pract 1995, 30:205-209.
69. Kalergis M., Schiffrin A., Gougeon R., et al. Impact of bedtime snack composition on prevention of nocturnal hypoglycemia in adults with type 1 diabetes undergoing intensive insulin management using lispro insulin before meals: a randomized, placebo-controlled, crossover trial. Diabetes Care 2003, 26:9-15.
70. Berger M., Berchtold P., Cüppers H.J., et al. Metabolic and hormonal effects of muscular exercise in juvenile type diabetics. Diabetologia 1977, 13:355-365.
71. Arutchelvam V., Heise T., Dellweg S., et al. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins. Diabet Med 2009, 26:1027-1032.
72. Cryer P.E. Banting Lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994, 43:1378-1389.
73. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 1991, 90:450-459. The DCCT Research Group.
74. Daneman D., Frank M., Perlman K., et al. Severe hypoglycemia in children with insulin-dependent diabetes mellitus: frequency and predisposing factors. J Pediatr 1989, 115:681-685.
75. Berlin I., Sachon C.I., Grimaldi A. Identification of factors associated with impaired hypoglycaemia awareness in patients with type 1 and type 2 diabetes mellitus. Diabetes Metab 2005, 31:246-251.
76. Schultes B., Jauch-Chara K., Gais S., et al. Defective awakening response to nocturnal hypoglycemia in patients with type 1 diabetes mellitus. PLOS Med 2007, 4:361-369.
77. Porter P.A., Byrne G., Stick S., et al. Nocturnal hypoglycaemia and sleep disturbances in young teenagers with insulin dependent diabetes mellitus. Arch Dis Child 1996, 75:120-123.
78. Gale E.A., Tattersall R.B. Unrecognised nocturnal hypoglycaemia in insulin-treated diabetics. Lancet 1979, 1:1049-1052.
79. Beregszàszi M., Tubiana-Rufi N., Benali K., et al. Nocturnal hypoglycemia in children and adolescents with insulin-dependent diabetes mellitus: prevalence and risk factors. J Pediatr 1997, 131:27-33.
80. Vervoort G., Goldschmidt H.M., van Doorn L.G. Nocturnal blood glucose profiles in patients with type 1 diabetes mellitus on multiple (> or = 4) daily insulin injection regimens. Diabet Med 1996, 13:794-799.
81. Davis E.A., Keating B., Byrne G.C., et al. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 1997, 20:22-25.
82. Ovalle F., Fanelli C.G., Paramore D.S., et al. Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus. Diabetes 1998, 47:1472-1479.
83. Dagogo-Jack S., Rattarasarn C., Cryer P.E. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994, 43:1426-1434.
84. Fanelli C., Pampanelli S., Epifano L., et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 1994, 37:1265-1276.
85. Dagogo-Jack S., Fanelli C.G., Cryer P.E. Durable reversal of hypoglycemia unawareness in type 1 diabetes. Diabetes Care 1999, 22:866-867.
86. Davis M., Mellman M., Friedman S., et al. Recovery of epinephrine response but not hypoglycemic symptom threshold after intensive therapy in type 1 diabetes. Am J Med 1994, 97:535-542.
87. Liu D., McManus R.M., Ryan E.A. Improved counter-regulatory hormonal and symptomatic responses to hypoglycemia in patients with insulin-dependent diabetes mellitus after 3 months of less strict glycemic control. Clin Invest Med 1996, 19:71-82.
88. Lingenfelser T., Buettner U., Martin J., et al. Improvement of impaired counterregulatory hormone response and symptom perception by short-term avoidance of hypoglycemia in IDDM. Diabetes Care 1995, 18:321-325.
89. Kinsley B.T., Weinger K., Bajaj M., et al. Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes. Diabetes Care 1999, 22:1022-1028.
90. Schachinger H., Hegar K., Hermanns N., et al. Randomized controlled clinical trial of Blood Glucose Awareness Training (BGAT III) in Switzerland and Germany. J Behav Med 2005, 28:587-594.
91. DeVries J.H., Lindholm A., Jacobsen J.L., et al. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with type 1 diabetes. Diabet Med 2003, 20:312-318. Tri-Continental Insulin Aspart Study Group.